Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
7.55 USD | +7.40% | -6.09% | +413.61% |
May. 30 | FDA Grants Candel Therapeutics' CAN-3110 Orphan Drug Designation to Treat Recurrent High-Grade Glioma | MT |
May. 30 | Candel Therapeutics Gets FDA's Orphan-Drug Status for Glioma Treatment | DJ |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+413.61% | 225M | |
+49.21% | 56.87B | |
+39.98% | 39.72B | |
-6.86% | 39.27B | |
-4.42% | 28.73B | |
+12.00% | 26.21B | |
-18.27% | 19.79B | |
+29.57% | 12.28B | |
+25.41% | 12.23B | |
-0.35% | 12.12B |
- Stock Market
- Equities
- CADL Stock
- News Candel Therapeutics, Inc.
- Candel Therapeutics Shares Surge Premarket Following 'Positive' Phase 2 Results From Non-Metastatic Pancreatic Cancer Trial